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Recurrent 
American 
Cutaneous 
Leishmaniasis
To the Editor: Leishmaniasis 
recidivans is an unusual clinical Old 
World disease primarily associated 
with  Leishmania tropica (1). Recur-
rence of previously cured cutaneous 
leishmaniasis (CL) lesions is found in 
American CL, for which a speciﬁ  c no-
sologic form known of disease known 
as leishmaniasis recidiva cutis (LRC) 
has been identiﬁ  ed.  Although  <30 
cases of LRC have been reported from 
Brazil, Colombia, Peru and Ecuador; 
these cases were caused mainly by L. 
braziliensis,  L.  amazonensis, and L.   
panamensis (2). We report 7 cases of 
recurrent American CL caused by L. 
guyanensis in French Guiana. 
Forty-eight military personnel 
who lived in France spent 3 months in 
French Guiana in 2004 and took part 
in a military training program in the 
rainforest for 15 days. Despite similar 
exposure conditions, American CL, 
conﬁ  rmed by positive direct examina-
tion of Giemsa-stained tissue smears, 
developed in 21 persons. These pa-
tients were treated with 1 or 2 courses 
of either 3 intravenous or 2 intramus-
cular injections of pentamidine isethi-
onate (4 mg/kg on alternate days). All 
lesions were cured 1–3 months after 
treatment had ended. Recurrence of 
the CL lesion was observed in 7 pa-
tients after a disease-free interval of 
3–6 months (Table). 
New lesions appeared on the edge 
of a healed scar for each patient, re-
gardless of the location of the primary 
lesion (Table), and were diagnosed at 
Rennes University Hospital (positive 
direct examination or culture) in 2005. 
For positive cultures, L.  guyanensis 
was identiﬁ  ed by genomic and isoen-
zymatic characterization at the Centre 
National de Référence des Leishmania, 
Université de Montpellier, Montpelli-
er, France. Patients were treated with 4 
intravenous injections of pentamidine 
isethionate (4 mg/kg every other day) 
and were cured without recurrence 
within 2 years. No differences in age 
or underlying diseases were noted in 
patients with recurrent CL.
L. (Viannia) guyanensis is highly 
prevalent in several leishmaniasis-
endemic areas of Brazil, Colombia, 
French Guiana, Guyana, Surinam, 
Peru, and Ecuador. This organism ac-
counts for >95% of the 5 Leishmania 
species found in French Guiana, com-
monly causes localized LCL, and oc-
casionally causes disseminated CL 
and mucocutaneous leishmaniasis (3). 
Dedet et al. reported that 6.8% of pa-
tients with CL caused by L. guyanen-
sis had a recurrent lesion at the site 
of a previously cured lesion, which 
occurred after a mean interval of 7.3 
months (4). A total of 33% of our pa-
tients had a cured primary infection in 
<3 months but they had a recurrence 
after a disease-free interval 3–6 months 
after treatment. 
Additional information on such a 
recurrent form of CL is needed. Clini-
cal symptoms in our patients were sug-
gestive of LRC as described by Berlin 
(1), i.e., a recurrence at the site of an 
original ulcer, generally within 2 years 
and often on the edge of a scar. LRC 
may not be uncommon in the New 
World but rather underreported (2). 
Few cases of LRC have been reported; 
these were caused by L. braziliensis, 
L.  amazonensis, and L.  panamensis 
(2,5,6). In CL caused by L. guyanensis, 
borderline clinical symptoms prevent 
clear distinction of the recurrent form 
of LRC from early treatment failures 
or reinfections. In our patients, the risk 
for reinfection was excluded because 
the military personnel lived in France 
and left French Guiana several months 
before the recurrence. 
Although pentavalent antimony 
is the recommended treatment for 
American CL, pentamidine isethion-
ate is widely used in French Guiana. 
Retrospective analysis showed that 
5%–25% of early treatment failures LETTERS
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occurred after 1 or 2 intramuscular in-
jections of 4–7 mg/kg of pentamidine 
isethionate, depending on different risk 
factors (7,8). Our observational study 
was not designed to evaluate treatment 
efﬁ  ciency; we observed 2 (9.5%) of 
21 early relapses and 7 (33%) of 21 
late-onset recurrences in this series. 
Although we lacked statistical power 
because of small numbers, a differ-
ence was observed in recurrence by 
treatment method in 7 (44%) of 16 
with recurrent disease who received 
3 intravenous pentamidine isethionate 
injections compared with 0 (0%) of 5 
who received 2 intramuscular injec-
tions. Re-treatment with a regimen of 4 
intravenous injections of pentamidine, 
under medical surveillance because of 
possible adverse effects, cured the dis-
ease. Physicians in countries in which 
L.  guyanensis is endemic should be 
aware of these complicated forms of 
CL after treatment, forms that prompt 
long-term follow-up and evaluation of 
speciﬁ  c therapeutic protocols.
Finally, the mechanism of late-
recurring leishmaniasis is poorly un-
derstood. Mendonça et al. suggested 
that clinical cure of American CL is 
rarely associated with sterile cure (i.e., 
elimination of the parasite) (9). Immu-
nologic data based on skin hypersensi-
tivity and histopathologic and immu-
nohistochemical ﬁ  ndings support the 
concept that LRC is a late-onset reac-
tivation after persistence of living par-
asites around or in cured leishmaniasis 
by as-yet unknown stimuli such as lo-
cal trauma (2 of our patients reported 
chronic lesions of the chin caused by 
a razor blade and 2 others had chroni-
cally scratched the scar lesion on their 
ears) or corticosteroid, and after an 
incomplete host immune response to 
an earlier episode (2, 5,10). Further 
immunologic studies of patients and 
identiﬁ  cation of genetic characteristics 
of L. guyanensis are needed to address 
this question.
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Table. Epidemiologic characteristics, strain identification, and treatment of 21 cases of American cutaneous leishmaniasis, French
Guiana, 2004–2005* 
Primary infection  Leishmaniasis recidiva cutis 
Case
no.
Lesion(s),
location
(no.) PI treatment† 
Time to 
healed
lesions, mo 
Disease-free
interval, mo 
Direct
examination
Strain
identification PI treatment  Outcome
1 Thorax (1)  IV, 4 mg/kg on 
alternate days 
× 3 
14 + Leishmania 
guyanensis
MON-45 
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
2 Right
forearm (1) 
IV, 4 mg/kg on 
alternate days 
× 3 
36 + L. guyanensis
MON-45 
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
3 Left leg (1) 
and chin (3) 
IV, 4 mg/kg on 
alternate days 
× 3 
1 4 + Negative
culture
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
4 Chin (3)  IV, 4 mg/kg on 
alternate days 
× 3 
1 4 + Negative
culture
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
5 Behind left 
ear (1) 
IV, 4 mg/kg on 
alternate days 
× 3 
13 + L. guyanensis
MON-131 
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
6 Left ear (1)  IV, 4 mg/kg on 
alternate days 
× 3 
1 6 + Negative
culture
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
7 Right ankle 
(5)
IV, 4 mg/kg on 
alternate days 
× 3 
2.5 4 + Negative
culture
IV, 4 mg/kg 
on alternate 
days × 4 
Cured
8–21 Various IV, 4 mg/kg on 
alternate days 
× 3 (for 9 
patients) or 
IM, 4 mg/kg 
on alternate 
days × 2 (for 5 
patients)†
1–3 – – – – –
*PI, pentamidine isethionate; IV, intravenous; IM, intramuscular.  
†IV versus IM administration of pentamidine isethionate was not associated with recurrent forms. LETTERS
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Leprosy as Immune 
Reconstitution 
Inﬂ  ammatory 
Syndrome in HIV-
positive Persons
To the Editor: More than 2 de-
cades ago, when HIV was ﬁ  rst  de-
tected, many investigators predicted 
the rise of leprosy secondary to op-
portunistic infection (1). Recently, the 
phenomenon of immune reconstitu-
tion inﬂ   ammatory syndrome (IRIS), 
or leprosy reversal response, has re-
ceived attention. IRIS often occurs 
secondary to initiating highly active 
antiretroviral therapy (HAART). The 
ﬁ  rst indications of an interaction be-
tween HIV and Mycobacterium leprae 
occurred only recently, with the iden-
tiﬁ   cation of IRIS after initiation of 
HAART in patients with HIV and pre-
viously undetected leprosy. A review 
by Pustianowski et al. discusses the 
paradox of HIV and leprosy with IRIS 
(2). In addition, Lawn et al. described 
the ﬁ  rst case of IRIS after the onset of 
HAART in a patient who had tubercu-
loid leprosy that was never conﬁ  rmed 
by molecular analysis (3). 
Multiple reports (4–7) unmasked 
subclinical Hansen disease (M. lep-
rae infection) occurring with HAART 
or spontaneously (8). In case reports 
by Lu et al. (6) and Sharma et al. (7), 
leprosy was associated with erythema 
nodosum leprosum. Pereira et al. dis-
covered that patients known to have 
HIV and leprosy, when treated with 
HAART manifested a type 1 reversal 
reaction, acute leprosy inﬂ  ammatory 
episode (4), or IRIS. We describe the 
ﬁ  rst, to our knowledge, 2 cases in the 
United States of HIV and leprosy in-
fections in which IRIS has occurred 
after HAART initiation and which has 
been conﬁ  rmed by molecular analysis.
Three skin-biopsy samples, 2 
from patient 1 and 1 from patient 2, 
were analyzed to conﬁ  rm the presence 
of M. leprae. Patient 1 met the diag-
nostic criteria for leprosy according 
to biopsy result; patient 2’s case was 
compatible  with such criteria. Each 
patient was treated for leprosy, and 
each responded favorably. The pur-
pose of our case study was to conﬁ  rm 
M. leprae DNA in skin samples. The 
skin specimens were parafﬁ  n-embed-
ded slides. DNA was extracted by 
standard molecular biologic methods 
that used xylene. PCR ampliﬁ  ed the 
M. leprae heat shock protein 65 gene 
(hsp65). After ampliﬁ  cation,  restric-
tion fragment-length polymorphism 
(RFLP)–polyacrylamide gel electro-
phoresis (PAGE) was performed with 
HaeIII (6).
Patient 1 was a 60-year-old His-
panic man who was ﬁ  rst evaluated in 
Los Angeles, California, with skin le-
sions covering >50% of his body. He 
reported having erythematous scaly 
plaques that had been waxing and 
waning for several months. Several 
skin biopsy samples were taken, and 
an HIV test was conducted; results 
showed that he had lepromatous lep-
rosy and was HIV positive. Biopsy 
specimens were both Fite stain posi-
tive for numerous acid-fast bacilli. 
Three months after HAART was initi-
ated, repeat skin biopsy samples were 
taken from nodules that had recently 
developed on his right arm and torso. 
Histologic assessment showed Fite 
stain–positive granulomatous derma-
titis with many foamy cells. He was 
treated for leprosy and is continuing 
HAART.
Patient 2 was a 37-year-old West 
African black man from Burkina Faso 
who was evaluated in New York for 
gram-negative bacteremia. He was 
admitted and treated for disseminat-
ed salmonellosis and was found to 
be HIV positive. His T-lymphocyte 
count was 7/μL. He was promptly 
prescribed HAART and responded 
well to treatment: his T-cell count 
rose to 112/μL during 5 months and 
is currently >700/μL. Within 2 years 
of HAART initiation, multiple anes-
thetic, hypopigmented skin macules 
that failed to resolve over 6 months 
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